With operations across 50 countries, MagicLab is pairing new robot systems with a platform strategy aimed at wider commercial adoption
Updated
May 1, 2026 2:16 PM
.jpg)
A standing yellow robotic arm. PHOTO: UNSPLASH
MagicLab Robotics is a Chinese startup that describes itself as an embodied AI company. At an event in Silicon Valley this week, it outlined its global ambitions and introduced new products designed for real-world use. The company said its international business now spans more than 50 countries and regions, with overseas markets accounting for 60% of total sales in 2025. That gives some indication of how quickly Chinese robotics firms are expanding beyond their home market.
At the centre of the announcement was MagicLab’s latest product line-up. It included Magic-Mix, described as a foundational world model for robots, the H01 dexterous robotic hand and its humanoid robot, MagicBot X1. In practical terms, the company is trying to build robots that can better understand their surroundings and perform physical tasks with greater precision. That is the core idea behind embodied AI, where intelligence is combined with movement and interaction in the real world rather than limited to software alone.
MagicLab says it develops both hardware and software internally. Its product range includes humanoid robots and four-legged machines, with systems designed for factories, commercial services and home use. The company also outlined where it sees demand emerging. It listed sectors such as healthcare, manufacturing, logistics, security, public safety, education and household assistance.
That wide spread of target markets reflects a broader challenge in robotics. Building capable machines is only one part of the equation. The harder task is finding enough practical uses where customers are willing to pay for them.
MagicLab also used the summit to set out a long-term commercial goal. It projected a path toward US$14 billion in annual revenue by 2036 through wider adoption of embodied AI systems. It also announced what it calls the “Co-Create 1000 Initiative”, a plan to work with external developers and partner companies.
As part of that effort, the startup said it plans to invest US$1 billion over the next five years to build a developer ecosystem that would allow third parties to create new applications for its robots. The strategy mirrors what happened in smartphones and cloud software, where ecosystems often mattered as much as the original hardware. If robotics follows a similar path, companies that attract developers could gain an advantage over those selling machines alone.
For now, MagicLab’s announcement is less about immediate breakthroughs and more about positioning. The company is presenting itself not simply as a robot maker, but as a platform business seeking a role in the next phase of intelligent machines.
Keep Reading
Reimagining biodefense at the intersection of AI, biology and urgency.
Updated
January 8, 2026 6:34 PM
Through computational tools, Valthos analyzes biological data to design adaptive solutions against emerging threats. PHOTO: VALTHOS
Valthos has raised US$30 million in seed funding, led by the OpenAI Startup Fund, Lux Capital and Founders Fund, to advance its mission of building next-generation biodefense systems.
The company’s work comes at a time when biotechnology is evolving at an unprecedented pace. Biotechnology is moving at record speed. These new tools can lead to life-changing medical discoveries, but they also bring the risk of dangerous biological agents being developed faster than ever.
“The issue at the core of biodefense is asymmetry”, said Kathleen McMahon, co-founder of Valthos. “It’s easier to make a pathogen than a cure. We’re building tools to help experts at the frontlines of biodefense move as fast as the threats they face”. The gap Valthos aims to close is between the rapid rise of biological threats and the slower pace of developing cures. Therefore, the company is developing AI systems that can rapidly analyze biological sequences and significantly shorten the time needed to design medical countermeasures.
“In this new world, the only way forward is to be faster. So we set out to build a new tech stack for biodefense”, said Tess van Stekelenburg, co-founder of Valthos. “This software infrastructure strengthens biodefense today and lays the groundwork for the adaptive, precision therapeutics of tomorrow”.
The company was founded by van Stekelenburg, a partner at Lux Capital and McMahon, the former head of Palantir’s Life Sciences division. Together, they’ve built a multidisciplinary team of experts from Palantir, DeepMind, Stanford’s Arc Institute and MIT’s Broad Institute, bringing together deep experience in software engineering, machine learning and biotechnology.
“Technology is moving fast. An industrial ecosystem of builders, companies and solutions further democratizes AI to provide broad resilience, and ensures the U.S. continues to lead as AI increasingly powers everything around us. As AI and biotech rapidly advance, biodefense is one of the new industry verticals that helps maximize the benefits and minimize the risks”, said Jason Kwon, OpenAI’s Chief Strategy Officer. “Valthos is pushing the frontier of protection and defense in one of the most strategic intersections of multiple world-changing technologies, and with the team to do it”.
Looking ahead, Valthos plans to expand its engineering team and scale its software infrastructure for both government and commercial partners — moving closer to its goal of enabling faster, smarter and more adaptive biodefense capabilities.